Search company, investor...

PNP Therapeutics


Series E | Alive

Total Raised


Last Raised

$120K | 4 yrs ago

About PNP Therapeutics

PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.

Headquarters Location

15 Richard Arrington Jr Blvd N

Birmingham, Alabama, 35203,

United States


Missing: PNP Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PNP Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PNP Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PNP Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

PNP Therapeutics Patents

PNP Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Animal anatomy
  • Body fluids
  • Developmental biology
patents chart

Application Date

Grant Date


Related Topics




Developmental biology, Feminine hygiene, Body fluids, Animal anatomy, Personal hygiene products


Application Date


Grant Date



Related Topics

Developmental biology, Feminine hygiene, Body fluids, Animal anatomy, Personal hygiene products



Latest PNP Therapeutics News

GeoVax Stock Is Trading Higher On Gedeptin In-Licensing Pact For Solid Tumors

Sep 29, 2021

Share: GeoVax Labs Inc (NASDAQ: GOVX )  entered into a license agreement  with PNP Therapeutics Inc to develop and commercialize Gedeptin for solid tumors. The transaction's detailed financial terms were not disclosed but include a combination of upfront payments, milestone fees, and royalties on net sales. A cycle of therapy consists of three intra-tumoral injections of Gedeptin over two days followed by infusion of a prodrug, fludarabine phosphate, once a day for three days. A Phase 1 dose-ranging study, evaluating the safety of a single cycle of Gedeptin therapy, found the treatment to be well-tolerated, with evidence of a reduction in tumor size in patients with solid tumors. A Phase 1/2 trial, evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options, is currently enrolling.

PNP Therapeutics Frequently Asked Questions (FAQ)

  • Where is PNP Therapeutics's headquarters?

    PNP Therapeutics's headquarters is located at 15 Richard Arrington Jr Blvd N, Birmingham.

  • What is PNP Therapeutics's latest funding round?

    PNP Therapeutics's latest funding round is Series E.

  • How much did PNP Therapeutics raise?

    PNP Therapeutics raised a total of $2.9M.

  • Who are the investors of PNP Therapeutics?

    Investors of PNP Therapeutics include Greer Capital Advisors, Birmingham Technology Fund and Qualifying Therapeutic Discovery Project.

  • Who are PNP Therapeutics's competitors?

    Competitors of PNP Therapeutics include Aquinox Pharmaceuticals, OncoMed Pharmaceuticals, Forte Biosciences, Syndax Pharmaceuticals, GlobeImmune and 11 more.

Compare PNP Therapeutics to Competitors

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..


Neotropix 1 is a virotherapy company, dedicated to the development and commercialization of virus-based therapies for the treatment of cancer and other diseases. Per Neotropix, virotherapy holds great promise for cancer patients because it may be more efficacious and less toxic than conventional radiation and chemotherapy.


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

The DNA Repair Company

The DNA Repair Company was founded to bring recent scientific discoveries from the Dana Farber Cancer Institute and the Massachusetts Institute of Technology to the clinic to benefit cancer patients. Breakthroughs in understanding DNA repair mechanisms have led to new personalized approaches to cancer treatment, beginning with diagnostic tools that improve the efficacy of currently available cancer therapies, as well as drugs under development. DNAR exists to make these tools available to physicians with the goal of improving clinical outcomes.

Oxford Genome Sciences (UK)

Oxford BioTherapeuticsis focused on the targeted treatment of cancer.


BioMs develops biologics for autoimmune diseases with a special emphasis on multiple sclerosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.